Microbiologics Expands Its Diagnostic Quality Controls
Microbiologics, a leader in biotechnology that specializes in infectious disease reference materials, has taken a significant step by acquiring SensID. This merger aims to enhance the quality of diagnostic solutions across various medical fields, particularly focusing on oncology and infectious diseases.
Enhancing Diagnostic Solutions
With this acquisition, both companies are poised to deliver superior diagnostic quality controls and reference materials. The integration of SensID into Microbiologics' operations will allow for a richer portfolio of products aimed at improving diagnostic accuracy for healthcare professionals worldwide.
Increased Expertise in Oncology
SensID, established in 2015 and known for its innovative approach, specializes in creating precisely characterized reference materials for molecular diagnostics. This expertise aligns seamlessly with Microbiologics' commitment to providing high-quality infectious disease diagnostics.
By combining their strengths, the newly united entity can expand research and development capabilities while ensuring comprehensive quality control solutions are accessible for diagnostic technology developers.
Strategic Focus on Patient Care
Kristen Knox, CEO of Microbiologics, expressed excitement about the merger, emphasizing its impact on patient care. She noted, "This partnership is about two organizations that share a deep commitment to improving the lives of patients through diagnostic advancements." The synergy between their technologies is anticipated to propel future innovations within the industry.
Continuity and Innovation
As the transition progresses, Microbiologics reassures its clients that there will be no disruption to ongoing projects. Both companies are dedicated to maintaining their mission of delivering outstanding products and services across the globe.
Commitment to High Standards
SensID is recognized for its dedication to quality and innovation, particularly its reference materials for oncology applications. This acquisition enhances Microbiologics' capacity to support molecular diagnostic tests, reflecting a shared mission for safety and excellence in patient care.
About Microbiologics and SensID
Microbiologics aims to protect global health through reliable diagnostic quality controls, contributing to the safety of infectious disease testing. The company collaborates with diagnostic technology developers to create tailored solutions for each stage of the diagnostic product lifecycle.
SensID focuses on the development and manufacturing of specialized reference materials, serving the oncology and pharmacogenomics sectors. Their products meet rigorous standards, making them invaluable for R&D and validation processes in the diagnostic testing realm.
Granite Partners has played an instrumental role in enabling this acquisition, further strengthening the alliance between Microbiologics and SensID. The firm strives to advance a culture of innovation and trust, essential for sustainability in today's competitive landscape.
Frequently Asked Questions
What is the significance of the Microbiologics and SensID acquisition?
The acquisition is crucial as it expands Microbiologics' offerings in oncology and enhances its diagnostic quality controls.
How will this impact patient care?
The merger aims to improve diagnostic capabilities, ultimately leading to enhanced patient care and safety across healthcare systems.
What are SensID's main areas of expertise?
SensID excels in creating reference materials for molecular diagnostics, particularly focusing on oncology and pharmacogenomics.
Will there be any disruption to existing partnerships after the acquisition?
Microbiologics has confirmed that there will be no disruption to ongoing partnerships and projects during the integration process.
Who is involved in advising the acquisition?
Granite Partners assisted in the acquisition, while various financial institutions provided necessary financing and advisory services through the process.
